Byondis B.V.

10 clinical trials · Sponsor

Record	Firm	Date
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors (NCT06932952)	Byondis B.V.	2025-05-07
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms. (NCT06359002)	Byondis B.V.	2024-06-25
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 (NCT05737628)	Byondis B.V.	2024-03-04
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 (NCT05323045)	Byondis B.V.	2022-03-21
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 (NCT04983238)	Byondis B.V.	2022-01-10
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors (NCT04235101)	Byondis B.V.	2020-06-22
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma (NCT04205630)	Byondis B.V.	2020-05-28
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 (NCT04202705)	Byondis B.V.	2020-02-28
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (NCT03262935)	Byondis B.V.	2017-12-15

Every clearance here is in the API, with alerts when new ones post.